(NASDAQ: NRSN) Neurosense Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.82%.
Neurosense Therapeutics's earnings in 2026 is -$11,125,000.On average, 5 Wall Street analysts forecast NRSN's earnings for 2026 to be -$10,515,967, with the lowest NRSN earnings forecast at -$12,762,412, and the highest NRSN earnings forecast at -$6,153,306. On average, 5 Wall Street analysts forecast NRSN's earnings for 2027 to be -$14,058,188, with the lowest NRSN earnings forecast at -$26,162,945, and the highest NRSN earnings forecast at -$6,495,156.
In 2028, NRSN is forecast to generate -$5,977,497 in earnings, with the lowest earnings forecast at -$7,976,508 and the highest earnings forecast at -$3,760,354.